Error loading player: No playable sources found
W107
Panel Discussion
Date
April 29, 2020
This product is not available for individual purchase, but it is available as part of the following products:
Speakers
Pfizer, Inc.
Genentech, a Member of the Roche Group
Amgen Inc.
CDER, FDA
Health Canada
Tracks
Related Products
Double Duty Bioassays: A Regulatory Perspective on Bispecific Antibody Bioassay Development
Bispecific product submissions to the United States Food and Drug Administration (FDA) have increased over recent years…
Bioassays for New Therapies
The number and diversity of biotherapeutic modalities continues to increase. These represent complex modalities such as peptide and peptide conjugates, antisense oligonucleotides, DNA- and RNA-based therapies, drug conjugates, as well as viral vector-based therapeutics…
Bioassays for Bispecifics – Double the Trouble or Double the Fun?
The structures and functions of modern biotherapeutics are becoming increasingly complex…
Bioassay Development Strategy for Bispecific Antibodies: Use of SPR Technology
ELISA binding assays are often used as fit-for-purpose potency assays at early stage of product development for monoclonal antibody and bispecific antibody products…
